Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Cash & Current Investments (2017 - 2025)

Dianthus Therapeutics (DNTH) has 7 years of Cash & Current Investments data on record, last reported at $401.6 million in Q3 2025.

  • For Q3 2025, Cash & Current Investments rose 42.86% year-over-year to $401.6 million; the TTM value through Sep 2025 reached $401.6 million, up 42.86%, while the annual FY2024 figure was $274.4 million, 58.99% up from the prior year.
  • Cash & Current Investments reached $401.6 million in Q3 2025 per DNTH's latest filing, up from $256.1 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $401.6 million in Q3 2025 and bottomed at $23.2 million in Q1 2023.
  • Average Cash & Current Investments over 4 years is $204.2 million, with a median of $189.9 million recorded in 2023.
  • Peak YoY movement for Cash & Current Investments: tumbled 85.18% in 2023, then skyrocketed 1524.32% in 2024.
  • A 4-year view of Cash & Current Investments shows it stood at $75.5 million in 2022, then soared by 128.62% to $172.6 million in 2023, then soared by 58.99% to $274.4 million in 2024, then surged by 46.37% to $401.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Current Investments were $401.6 million in Q3 2025, $256.1 million in Q2 2025, and $262.4 million in Q1 2025.